Literature DB >> 33550440

Transforming type 1 diabetes: the next wave of innovation.

Daniel J Drucker1.   

Abstract

The discovery of insulin in 1921 enabled pharmaceutical production of animal insulins for the treatment of people with type 1 diabetes by 1922. The last several decades have witnessed enormous scientific progress in the therapy of type 1 diabetes, yet some developments have been incremental, and insulin is not a cure. Herein, I highlight key scientific advances potentially poised to improve the quality of life and treatment outcomes in type 1 diabetes. These innovations range from newer insulin analogues to the development of smart insulins, oral and weekly insulins, glucose sensors and closed-loop insulin-delivery devices, as well as strategies for durable human beta cell replacement coupled with selective immune manipulation to preserve beta cell function. Finally, progress in the prediction and prevention of type 1 diabetes highlights the ongoing challenges and potential for altering the natural history of the disease or eliminating type 1 diabetes altogether.

Entities:  

Keywords:  Autoimmunity; Glucose; Immunology; Insulin; Pancreas; Pumps; Review; Stem cells

Mesh:

Substances:

Year:  2021        PMID: 33550440     DOI: 10.1007/s00125-021-05396-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  14 in total

1.  Linking a cell-division gene and a suicide gene to define and improve cell therapy safety.

Authors:  Qin Liang; Claudio Monetti; Maria V Shutova; Eric J Neely; Sabiha Hacibekiroglu; Huijuan Yang; Christopher Kim; Puzheng Zhang; Chengjin Li; Kristina Nagy; Maria Mileikovsky; Istvan Gyongy; Hoon-Ki Sung; Andras Nagy
Journal:  Nature       Date:  2018-11-14       Impact factor: 49.962

2.  Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.

Authors:  Inge B Halberg; Karsten Lyby; Karsten Wassermann; Tim Heise; Eric Zijlstra; Leona Plum-Mörschel
Journal:  Lancet Diabetes Endocrinol       Date:  2019-01-21       Impact factor: 32.069

3.  An ingestible self-orienting system for oral delivery of macromolecules.

Authors:  Alex Abramson; Ester Caffarel-Salvador; Minsoo Khang; David Dellal; David Silverstein; Yuan Gao; Morten Revsgaard Frederiksen; Andreas Vegge; František Hubálek; Jorrit J Water; Anders V Friderichsen; Johannes Fels; Rikke Kaae Kirk; Cody Cleveland; Joy Collins; Siddartha Tamang; Alison Hayward; Tomas Landh; Stephen T Buckley; Niclas Roxhed; Ulrik Rahbek; Robert Langer; Giovanni Traverso
Journal:  Science       Date:  2019-02-08       Impact factor: 47.728

Review 4.  Advances in oral peptide therapeutics.

Authors:  Daniel J Drucker
Journal:  Nat Rev Drug Discov       Date:  2019-12-17       Impact factor: 84.694

5.  Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.

Authors:  Hillary A Keenan; Jennifer K Sun; Jared Levine; Alessandro Doria; Lloyd P Aiello; George Eisenbarth; Susan Bonner-Weir; George L King
Journal:  Diabetes       Date:  2010-08-10       Impact factor: 9.461

6.  Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes.

Authors:  Jeffrey A Bluestone; Qizhi Tang
Journal:  Cell Stem Cell       Date:  2020-10-01       Impact factor: 24.633

7.  Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.

Authors:  Julio Rosenstock; Harpreet S Bajaj; Andrej Janež; Robert Silver; Kamilla Begtrup; Melissa V Hansen; Ting Jia; Ronald Goldenberg
Journal:  N Engl J Med       Date:  2020-09-22       Impact factor: 91.245

8.  GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration.

Authors:  Courtney Ackeifi; Peng Wang; Esra Karakose; Jocelyn E Manning Fox; Bryan J González; Hongtao Liu; Jessica Wilson; Ethan Swartz; Cecilia Berrouet; Yansui Li; Kunal Kumar; Patrick E MacDonald; Roberto Sanchez; Bernard Thorens; Robert DeVita; Dirk Homann; Dieter Egli; Donald K Scott; Adolfo Garcia-Ocaña; Andrew F Stewart
Journal:  Sci Transl Med       Date:  2020-02-12       Impact factor: 17.956

9.  Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus.

Authors:  E R Seaquist; L Blonde; J B McGill; S R Heller; D M Kendall; J B Bumpass; F M Pompilio; M L Grant
Journal:  Diabet Med       Date:  2019-12-19       Impact factor: 4.359

10.  Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.

Authors:  Athena Philis-Tsimikas; David C Klonoff; Kamlesh Khunti; Harpreet S Bajaj; Lawrence A Leiter; Melissa V Hansen; Lone N Troelsen; Steen Ladelund; Simon Heller; Thomas R Pieber
Journal:  Diabetologia       Date:  2020-01-27       Impact factor: 10.122

View more
  2 in total

Review 1.  Recent advances in closed-loop insulin delivery.

Authors:  Julia Ware; Roman Hovorka
Journal:  Metabolism       Date:  2021-12-07       Impact factor: 8.694

Review 2.  Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions.

Authors:  Marco Infante; David A Baidal; Michael R Rickels; Andrea Fabbri; Jay S Skyler; Rodolfo Alejandro; Camillo Ricordi
Journal:  Artif Organs       Date:  2021-07-15       Impact factor: 2.663

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.